CMV-SPECIFIC CELLULAR IMMUNITY IN RECIPIENTS OF ALLOGENIC BONE MARROW TRANSPLANT

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是确定是否实验测试免疫CMV可以确定何时免疫这种病毒是移植后存在，以及测试是否可以预测，一个人是保护从严重的CMV感染移植后。参与这项研究预计将持续约5天的捐助者，并为1年的移植受体。 保护自己免受CMV感染的能力称为CMV特异性细胞免疫。这种免疫力是决定移植后是否会发生严重CMV感染的最重要因素之一。有多种方法可以测量这种免疫力。最重要的方法之一是确定您的淋巴细胞（细胞免疫）是否可以杀死CMV感染的细胞。这被称为CTL测定。众所周知，发展良好CTL水平的人在移植后对严重CMV感染具有保护作用。CTL测试很难执行，并且已经开发了一种实验测试来试图预测一个人是否具有免疫力。这种实验性测试被称为HLA-肽四聚体结合测定（TBA），尽管已知TBA在试管中工作良好，但尚未在接受移植的人中进行评估。这项研究的目的是确定如何最好地为移植患者进行TBA测试，并确定您的TBA水平是否可以预测您是否会在移植后免受CMV感染或疾病的影响。本研究的另一个目标是确定您的治疗对您的CMV免疫水平的影响，这些免疫水平是通过本实验测试和其他免疫测试测量的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine whether an experimental test for immunity to CMV can determine when immunity to this virus is present after transplantation and whether the test can predict that a person is protected from serious CMV infections after transplantation. Participation in this study is expected to last approximately 5 days for donors, and for 1 year for transplant recipients. An ability to protect yourself from CMV infection is called CMV-specific cellular immunity. This immunity is among the most important factors that determine whether you will get a serious CMV infection after transplantation. There are various ways to measure this immunity. One of the most important ways is to determine if your lymphocytes (cell immunity) can kill CMV-infected cells. This is called a CTL assay. It is known that persons who develop good CTL levels have protection against severe CMV infection after transplantation. The CTL test is difficult to perform and an experimental test has been developed to try to predict whether or not a person is immune. This experimental test is called the HLA-peptide tetramer binding assay (TBA), and, although it is known that the TBA works well in the test tube, it has not yet been evaluated in persons undergoing transplantation. The goals of this study are to determine how best to perform the TBA test for transplant patients and to determine whether or not your TBA levels predict whether you will be protected from CMV infection or disease after transplant. Another goal of this study will be to determine what effects your treatments have on your levels of CMV immunity as measured by this experimental test and other tests of immunity.